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Hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma worldwide. HCV
establishes a chronic infection in the majority of cases. However, some individuals clear the virus,
demonstrating a protective role for the host immune response. Although new all-oral drug combinations
may soon replace traditional ribavirin–interferon therapy, the emerging drug cocktails will be expensive
and associated with side-effects and resistance, making a global vaccine an urgent priority. T cells are
widely accepted to play an essential role in clearing acute HCV infection, whereas the role antibodies play
in resolution and disease pathogenesis is less well understood. Recent studies have provided an insight
into viral neutralizing determinants and the protective role of antibodies during infection. This review
provides a historical perspective of the role neutralizing antibodies play in HCV infection and discusses
the therapeutic beneﬁts of antibody-based therapies. This article forms part of a symposium in Antiviral
Research on ‘‘Hepatitis C: next steps toward global eradication.’’
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Hepatitis C virus (HCV) has established chronic infection in
approximately 170 million people worldwide and can lead to
cirrhosis and hepatocellular carcinoma (HCC). Antiviral therapieshave largely relied on interferon-based regimes that were poorly
tolerated and ineffective in the majority of patients (Jesudian
et al., 2013). It is unclear whether the new battery of direct acting
antiviral therapies will cure hepatitis C in all cases, especially those
infected with genotype 3 viruses or with co-morbidities, such as
cirrhosis and HIV co-infection (Lange et al., 2014), highlighting
the need for alternative immune-based therapies. At present there
is no prophylactic or therapeutic HCV vaccine. HCV is amongst the
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infection or be cleared, demonstrating a protective role for the
adaptive immune response in some individuals. Our current goal
is to understand the determinants of a protective immune
response and whether recombinant vaccines can induce such
responses.
2. In vitro systems to measure HCV-speciﬁc neutralizing
antibodies
Prior to the development of in vitro infection systems, the neu-
tralizing potential of HCV-speciﬁc antibodies were evaluated using
‘‘neutralization of binding’’ assays (NOB), where antibodies were
screened for their ability to prevent recombinant viral E2 glycopro-
tein binding to mammalian cells (Rosa et al., 1996). Baumert and
colleagues developed a recombinant baculovirus system to express
the HCV structural proteins which formed viral-like particles
(VLPs) (Baumert et al., 1998) to study antibody reactivity and inhi-
bition of VLP-cell interactions (Baumert et al., 2000). However, the
discovery that lentiviral pseudoparticles expressing HCV glycopro-
teins (HCVpp) were infectious for hepatocytes and hepatoma cell
lines (Bartosch et al., 2003b; Hsu et al., 2003) superseded these
model systems and enabled studies to unravel the mechanism of
HCV entry and to measure functional neutralizing antibody re-
sponses for the ﬁrst time.
HCV encodes two envelope glycoproteins, E1 and E2, both of
which are required for pseudoparticle infectivity. HCVpp infect pri-
mary human hepatocytes and hepatoma cell lines via a clathrin
mediated endocytosis (Blanchard et al., 2006; Meertens et al.,
2006) that is dependent on four essential host cell molecules:
tetraspanin CD81; scavenger receptor class B member I (SR-BI)
and tight junction proteins claudin-1 and occludin (Meredith
et al., 2012; Zeisel et al., 2013). The HCVpp system has
enabled the screening and identiﬁcation of polyclonal sera
(Bartosch et al., 2003a,c; Flint et al., 2004; Logvinoff et al., 2004;
Sung et al., 2003; Yu et al., 2004) and monoclonal antibodies (Giang
et al., 2012) that inhibit infection, demonstrating the cross-reactive
nature of neutralizing antibody responses that are independent of
the infecting or immunizing viral genotype, providing an impetus
for developing antibody based therapeutics.
Early studies with the HCVpp system suggested that neutraliz-
ing antibodies were frequently observed in chronically infected
subjects, raising the question as to how the virus can persist in
the face of this response. However, serum antibodies are generally
screened for the ability to neutralize a limited number of viral
genotypes (Bartosch et al., 2003a; Broering et al., 2009). Recent
studies using HCVpp expressing a panel of glycoproteins cloned
from clinical material demonstrate differences in sensitivity to
antibody neutralization, in contrasts the most commonly used
H77c viral strain was easily neutralized by the majority of sera
(Tarr et al., 2011; Osburn et al., 2014).
The discovery that the JFH-1 strain of HCV could generate infec-
tious particles in cell culture (HCVcc) revolutionized the viral hep-
atitis ﬁeld and allowed investigators to study the sensitivity of
authentic viral particles to antibody-dependent neutralization
(Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005).
To date, HCVcc has been reported to be neutralized in vitro by
E2-speciﬁc antibodies derived from human sera (Lindenbach
et al., 2005; Zhong et al., 2005), polyclonal Ig preparations derived
from E1E2 immunized mice and guinea pigs (Stamataki et al.,
2007) and by a diverse array of glycoprotein-speciﬁc monoclonal
antibodies (mAbs) (Johansson et al., 2007; Keck et al., 2008; Law
et al., 2008; Meunier et al., 2008; Pedersen et al., 2013; Perotti
et al., 2008). The JFH-1 system can be modiﬁed to study the prop-
erties of genetically diverse viruses by the generation of chimeric
clones encoding the structural proteins (core, E1, E2 and p7) andpart of the non-structural protein 2 (NS2) of all major genotypes.
Chimeras constructed using genotype 2 structural proteins repli-
cate with similar kinetics to wild type virus without cell culture
adaptation and have recently been used to conﬁrm that cell entry
mediated by patient-derived E1E2 is relatively resistant to neutral-
ization by polyclonal serum (Pedersen et al., 2013).
The JFH-1 system has also been used as a backbone to construct
inter-genotype chimeras, but these often show poor replication
kinetics and acquire cell-culture adaptive mutations (Gottwein
et al., 2009; Pietschmann et al., 2006). There is emerging evidence
that at least some culture-adaptive mutations render the strains
more sensitive to antibody neutralization (Dhillon et al., 2010;
Grove et al., 2008). Therefore, a HCV-based single-cycle infection
system, particularly one that could be complemented with E1E2
cloned directly ex vivo, would provide a more robust method to
study antibody neutralization. Trans-complementation of HCV
replicons with plasmids encoding the HCV structural proteins re-
sults in the production of infectious particles containing a pack-
aged replicon genome (Adair et al., 2009). However, the relatively
low virus titers produced limits the general applicability of this
system.
A small animal model capable of supporting the complete
replicative cycle would be invaluable to study the role of anti-
bodies in HCV infection (Billerbeck et al., 2013; Mailly et al.,
2013). The uPA-SCID mouse model uses immunosuppressed
mice transplanted with human hepatocytes, which renders
them susceptible to HCV infection (Mercer et al., 2001). Gener-
ation of chimeric livers is technically difﬁcult and the mice are
immunodeﬁcient, limiting studies on host adaptive immunity.
However, this model has been invaluable to conﬁrm the efﬁcacy
of passively transferred antibodies to protect animals against
challenge virus (Law et al., 2008; Vanwolleghem et al., 2008).
More recently, transgenic immunocompetent mice expressing
the essential HCV entry factors were reported to support HCV
replication and administration of adenoviral expressed HCV gly-
coproteins induced antibody responses that limit infection
(Dorner et al., 2013, 2011).3. Do neutralizing antibodies inﬂuence HCV replication?
Due to the asymptomatic nature of acute HCV infection, iden-
tifying and studying patients in the early phase of infection is
difﬁcult. HCV infected individuals frequently have detectable
RNA levels as early as one week following infection, however
adaptive immune responses against the virus are not detected
for several months (Chen et al., 1999). Several studies of acute
HCV infection demonstrate that a broad and potent T cell
response is important for virus clearance (reviewed in
(Neumann-Haefelin and Thimme, 2013; Rehermann, 2013) and
that the rapid induction of cross-reactive nAb responses associates
with spontaneous recovery (Dowd et al., 2009; Pestka et al.,
2007; Osburn et al., 2014). Limited studies of HCV evolution
during acute infection show that resolving patients have stable
HVR1 sequences, whereas chronically infected subjects show
more noticeable HVR1 sequence change (Farci et al., 2000; Ray
et al., 1999). The role of the humoral response in selecting viral
diversity, particularly in the HVR, was reinforced by reports that
HCV-infected subjects with hypogammaglobulinemia showed re-
duced rates of nucleotide substitution in the HVR compared to
controls (Booth et al., 1998). The authors propose that the HVR
serves as a ‘‘viral decoy’’, directing the immune system away
from viral epitopes potentially less capable of rapid change
and towards those where faster rates of evolution can be
tolerated (Liu et al., 2010; Mondelli et al., 2001; Ray et al.,
1999; von Hahn et al., 2007).
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sponses were carried out with chimpanzees, showing that sera
from infected animals could neutralize virus infectivity in vitro
and subsequently protect chimpanzees against HCV challenge
(Farci et al., 1996). In a separate study, chimpanzees immunised
with E1E2 envelope glycoproteins elicited an antibody response
that partially protected against experimental challenge with autol-
ogous HCV (Choo et al., 1994). More recently, transfusion of human
monoclonal antibody (HCV1) mapping to E2 amino acids 412–423
protected a naïve chimpanzee from HCV challenge and reduced
viral RNA levels in an acutely infected animal (Morin et al.,
2012). Evidence that antibodies can protect humans arose from a
retrospective cohort study of patients receiving polyclonal immu-
noglobulin against hepatitis B virus surface antigen (HBIG). Pa-
tients who received HBIG prior to the introduction of routine
screening of blood donors for HCV infection were less likely to ac-
quire HCV than those who received HBIG screened for HCV (Yu
et al., 2004). Anti-HCV antibodies were detected in HCV-negative
patients who had undergone HBIG treatment, suggesting a passive
transfer of anti-HCV antibodies in HBIG to the recipient (Feray
et al., 1998). This highlights the potential use of therapeutic anti-
bodies for the prevention of HCV infection, especially in the liver
transplant setting where early clinical trials were disappointing
(Schiano et al., 2006; Davis et al., 2005) however a recent study re-
ported that a humanized monoclonal antibody MBL-HCV1 delayed
HCV RNA kinetics (Chung et al., 2013).
Even in chronically infected individuals, there is evidence that
antibodies may partially control HCV replication. Firstly, hypo-
gammaglobulinaemic individuals exhibit a marked rapidity and
severity in disease progression (Bjoro et al., 1994). Secondly, B cell
depletion during rituximab therapy leads to an increase in periph-
eral viral load, which returns to normal after cessation of therapy
(Ennishi et al., 2008). Zibert et al. reported that 43% of individuals
who spontaneously resolved infection had antibodies speciﬁc to
the E2 hypervariable (HVR) region within the ﬁrst 6 months of
infection, compared to only 13% of patients who failed to clear
infection (Zibert et al., 1997). In contrast, there were no signiﬁcant
differences between patient groups with respect to the time of
emergence of antibodies to HCV core or non-structural proteins.
Other investigators reported an early emergence of HVR1-speciﬁc
antibodies in a cohort of subjects infected during haemodialysis
who resolved infection (Allander et al., 1997). Since the HVR1 is
proposed to be a target for neutralizing antibodies (Farci et al.,
1996; Kato et al., 1993), several studies suggest a role of anti-
HVR1 antibodies in selecting viral variants to escape the humoral
response (Booth et al., 1998; Liu et al., 2010; Ni et al., 1999; van
Doorn et al., 1995; von Hahn et al., 2007). A recent case study dem-
onstrated that spontaneous clearance of chronic HCV infection
associated with the appearance of neutralizing antibodies and a
reversal of T-cell exhaustion (Raghuraman et al., 2012). It is likely
that during chronic infection there is a dynamic interplay between
host and virus such that mutations that lead to immune escape
may also reduce viral ﬁtness.4. Fc-effector function of antibodies
The antibody Fc region plays an essential role in controlling
chronic viral infections (Hessell et al., 2007) and can mediate anti-
body dependent cellular cytotoxicity (ADCC), complement-depen-
dent cytotoxicity (CDC) or antibody-dependent phagocytosis by
cells possessing Fcc receptors. Our level of understanding on the
role of antibody Fc-mediated antibody activity in controlling HCV
replication is limited. A single report suggests that antibodies
targeting HCV E2 can mediate ADCC (Nattermann et al., 2005). A
signiﬁcant role for complement to limit HCV infection is emerging.Recent studies suggest that HCV has evolved to evade complement
mediated lysis, via down-regulation of complement factors
(Banerjee et al., 2011; Kim et al., 2013; Mazumdar et al., 2012)
and incorporation of host CD55 and CD59 into virus particles
(Amet et al., 2012; Ejaz et al., 2012; Mazumdar et al., 2013).
Antibody-mediated neutralization of HCV in vitro is enhanced in
the presence of complement (Machida et al., 2008; Meyer et al.,
2002), suggesting a potential role for antibody isotypes to play a
role in viral clearance in vivo. Antibody-dependent phagocytosis
of HCV by anti-E2 antibodies was reported to occur and was
enhanced by complement (Eren et al., 2006).
In addition to contributing to clearance, Fc-mediated effects
may be detrimental and non-neutralizing monoclonal antibodies
have been reported to enhance HCV pseudotype infectivity by pro-
moting interaction with FccRII and FccRI on target cells (Meyer
et al., 2008). Furthermore, polyclonal serum antibodies isolated
from the sera of chronic HCV infected patients have been reported
to enhance infection (Tarr et al., 2011). The interplay between pro-
tection and enhancement of infection has implications for success-
ful antibody-based therapy and highlights the need to study the
impact of isotype and Fc-dependent functions on the antiviral
activity of antibodies targeting the HCV glycoproteins.5. Neutralizing antibody epitopes
nAbs exert their effect(s) by binding directly to virus particles
and blocking subsequent interaction(s) with receptors or by inhib-
iting post entry events such as viral uncoating and subsequent rep-
lication (Burton, 2002). The former may occur by inducing
conformational changes in the viral envelope that disable infection
or by steric hindrance, physically shielding important viral interac-
tion sites. The epitopes recognized by neutralizing antibodies map
to the viral encoded E1E2 envelope glycoproteins and the majority
of reported antibodies block CD81 receptor interaction (Fig. 1) (Hsu
et al., 2003; Johansson et al., 2007; Keck et al., 2008, 2012; Meunier
et al., 2008; Perotti et al., 2008). Early chimpanzee studies identi-
ﬁed the HVR in the E2N-terminus as a major target for neutralizing
antibodies. This region possesses multiple linear epitopes between
amino acids (aa) 384–410 that are important for antibody recogni-
tion and binding scavenger receptor class B type I (SR-BI), a lipo-
protein receptor molecule essential for HCV entry (Bartosch
et al., 2003c; Scarselli et al., 2002). Antibodies targeting the
HVR1 were observed in vivo (Kato et al., 1994, 1993; Weiner
et al., 1992; Zucchelli et al., 2001); however not surprisingly
anti-HVR antibodies show strain-speciﬁc neutralizing activity
(Fig. 2). In an attempt to overcome their limited reactivity, Zucch-
elli and colleagues generated peptide mimics representing diverse
HCV sequences that induced antibody responses capable of recog-
nizing diverse patient derived variants (Zucchelli et al., 2001). Re-
cent studies show that viruses lacking a HVR1 are more susceptible
to neutralization by a panel of human mAbs and patient sera, sug-
gesting that the HVR1 masks the E2-CD81 binding site (Bankwitz
et al., 2010; Prentoe et al., 2011).
The lack of broadly neutralizing antibodies targeting the HVR1
led to the search for conserved epitopes. Whilst neutralizing anti-
bodies targeting conserved epitopes overlapping the SR-BI binding
site (Sabo et al., 2011), discontinuous residues not involved in
CD81 binding (Giang et al., 2012) and E1 determinants (Meunier
et al., 2008) have been described, the majority of neutralizing anti-
bodies target the CD81 binding site (Johansson et al., 2007; Law
et al., 2008; Owsianka et al., 2005, 2008; Perotti et al., 2008). Anti-
body competition studies provided the ﬁrst insight into the region
of E2 involved in CD81 binding and subsequent mutagenesis stud-
ies identiﬁed an essential role for residues W420, Y527, W529, G530
and D535 (Owsianka et al., 2006) and 436GWLAGLFY443 in binding
Fig. 1. Neutralizing activity of anti-HCV antibodies and nanobodies. HCV particles circulate as lipoviral particles (LVPs) in the blood, in complex with low-density
lipoproteins. Antibody epitopes are accessible on these LVPs. In an established infection, naïve cells can be infected by extracellular virus or by direct cell–cell transmission
between adjacent cells. Antibody-mediated neutralization can occur as particles are released from infected cells (1), preventing HCV entry into naïve hepatocytes. While
antibody based therapy appears to inhibit the extracellular route of infection, nanobodies (blue oval) have recently been demonstrated to inhibit the direct transmission of
HCV between cells. It remains to be determined if this neutralizing activity is mediated via the blockade of cell-tethered virus (2), or direct inhibition of virus transmission
between cell–cell junctions (3).
Fig. 2. Variation in the HCV E2 glycoprotein N-terminus. Diversity of HCV E2N-terminal aa 384–429. (A) An entropy plot was performed to measure variability across viral
strains – within HVR1 (aa 384–410), functionally conserved residues are observed at positions 385, 406 and 409. The well-described ‘Epitope I’ conserved region (Zhang et al.,
2007) contains epitopes of neutralizing mAbs AP33, 3/11 (Tarr et al.) and HCV1 (Kong et al., 2012a,b). (B) A Kyte-Doolittle hydrophobicity plot reveals the hydrophobic nature
of the HVR1 between patient sequences. (C) Residues responsible for cross reactivity of antibodies directed to the HVR1 are highlighted on HCV reference H77 strain. These
residues are co-incident with regions possessing hydrophilic amino acids that are likely to be exposed on the surface of the virus particle.
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CD81 binding site can be divided into three groups depending on
whether they recognise: (i) linear epitopes located between E2
amino acids 412–423 (e.g. murine mAbs AP33, 3/11); (ii)conformational epitopes where key contact residues are located
between residue 529 and 535 (e.g. human mAbs 1:7, A8, CBH2);
or (iii) epitopes spanning these two CD81 binding regions (e.g.
AR3A, AR3C, e137). Importantly, the most potent and broadly
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amino acid residues 412–423, whereas human antibodies to this
region are rare (Tarr et al., 2007). In contrast, the majority of neu-
tralizing human antibodies recognize conformation-sensitive epi-
topes centred on the key CD81 binding residues W529, G530 and
D535 (Owsianka et al., 2006).
Antibodies targeting epitopes within the envelope glycoprotein
E1 have been identiﬁed in some patients, but are generally rare
(Pestka et al., 2007). This may reﬂect the technical difﬁculties in
detecting anti-E1 responses, as the protein misfolds unless co-ex-
pressed with E2 (Dubuisson et al., 1994). Previous trials of E1 gly-
coprotein vaccine candidates induced antibody responses (Garrone
et al., 2011; Leroux-Roels et al., 2004; Nevens et al., 2003) that had
minimal effect on peripheral HCV RNA levels in chronically in-
fected patients (Nevens et al., 2003). However, a recent study in
chimpanzees showed that immunization with recombinant E1 pro-
tected animals against experimental infection with heterologous
HCV (Verstrepen et al., 2011). Due to the limited understanding
of the role and structure of E1 and how it interacts with E2, the
mechanism of protection and whether it is antibody-dependent
is unknown. It is important to note that E1 has been reported to
contain a putative fusion peptide (Lavillette et al., 2007; Flint
et al., 1999b) that may provide a target for neutralizing antibodies
based on the HIV-1 and inﬂuenza literature (Karlsson Hedestam
et al., 2008; Shui et al., 2009).
Zhang and colleagues reported the presence of anti-E2 antibod-
ies binding aa 434–446 in patient and chimpanzee immune-sera
that interfered with the activity of nAbs targeting epitopes located
between residues aa 412–423 (Zhang et al., 2007, 2009). The
authors suggest that the presence of such inhibitory antibodies
may explain the failure of anti-HCV polyclonal immunoglobulin
preparations to prevent HCV infection in the liver transplant set-
ting (Davis et al., 2005). Subsequent studies by the same group,
using murine monoclonal antibodies, argued that E2 aa 427–446
was targeted by interfering and non-interfering non-neutralizing
antibodies. However, interference was only demonstrated with
chimpanzee serum antibodies immunopuriﬁed with peptide
aa-412–423 and furthermore the afﬁnity the non-neutralizing
antibodies for aa 427–446 peptide was low compared to the
corresponding neutralizing antibodies targeting the same peptide
(Duan et al., 2012). The interfering antibody hypothesis contradicts
earlier observations made by Feray et al. where polyclonal
immunoglobulins were found to protect against HCV infection
(Feray et al., 1998). In addition, we (Tarr et al., 2012) and others
(Keck et al., 2013) reported that human and murine antibodies
targeting epitopes within aa 434–446 neutralize HCVpp and HCVcc
and show additive neutralization with antibodies targeting aa
412–423.6. Strategies for HCV to escape neutralizing antibodies
The most widely reported viral evasion mechanism is muta-
tional escape. HCV contains a single-stranded positive-sense RNA
genome that is replicated by a virus-encoded RNA-dependent
RNA polymerase. This polymerase lacks proof-reading capabilities
which, when coupled with the high replication rate of the virus, re-
sults in the generation of a diverse population of viral variants or
quasispecies (Simmonds, 2004). This virus population can harbour
neutralization escape variants that have a selective advantage over
sensitive variants. Positively selected amino acids are located with-
in and around known receptor- and neutralizing antibody-binding
regions (Brown et al., 2005, 2007). E1E2 evolution is driven by the
neutralizing antibody response and escape variants can become
the dominant circulating strain (Dowd et al., 2009; Farci et al.,
2000; von Hahn et al., 2007). Both von Hahn et al. and Dowdet al. reported that sequential sera show a limited ability to neu-
tralize concurrent circulating viral strains but efﬁciently neutralize
virus strains from earlier time points (Dowd et al., 2009; von Hahn
et al., 2007). Concluding that a single viral envelope sequence is
unlikely to represent the population of viruses within the liver.
The most broadly neutralizing antibodies reported to date tar-
get the CD81 binding site, and HCV has evolved various methods
of shielding this region of the glycoprotein. E2 contains up to 11
potential N-linked glycosylation sites, nine of which are conserved
across genotypes (>97%) (Helle et al., 2007). Glycans are important
for the structure and function of glycoproteins and are critical for
HCVpp entry into target cells (Goffard et al., 2005; Falkowska
et al., 2007). Speciﬁc glycans are known to mask the CD81 binding
site and mutation of these sites leads to increased CD81 binding
and sensitivity to neutralization by patient sera and mAb (Falk-
owska et al., 2007; Helle et al., 2007, 2010; Pantua et al., 2013).
Changes occur in the frequency and position of glycans on both
HIV-1 gp120 and inﬂuenza HA glycoproteins, and these ‘‘evolving
glycan shields’’ limit virus sensitivity to antibody neutralization
(Abe et al., 2004; Wei et al., 2003). Whilst there is some variability
in the location and number of glycosylation sites across different
HCV E1E2 sequences (Helle et al., 2007), particularly in genotype
3 viruses (Brown et al., 2007) (Anjum et al., 2013; Humphreys
et al., 2009), there is limited evidence for glycans to undergo signif-
icant intra-host evolution (Brown et al., 2007; Helle et al., 2007).
More recently, HCV was reported to transmit via cell-to-cell
junctions, providing an additional mechanism to escape neutraliz-
ing antibodies (Brimacombe et al., 2011; Timpe et al., 2007;
Witteveldt et al., 2009). Many enveloped viruses, including herpes
simplex virus, human T cell lymphotropic virus, HIV and measles
virus transmit via cell-to-cell junctions to evade host immune re-
sponses (Mothes et al., 2010). The exact mechanism of HCV cell-
to-cell transmission is still unknown but is dependent on the same
viral receptors and ApoE as extracellular virus particles. Tarr and
colleagues recently reported that a nanobody targeting the E2-
CD81 binding site could inhibit cell-to-cell infection, suggesting
that transmitting virus is not located in a synapase that is inacces-
sible to antibodies and that the lower molecular weight of the
nanobody may promote access to cell-tethered virus (Tarr et al.,
2013).7. Inducing protective immunity in vivo
The propensity for HCV to establish chronic infection, to re-in-
fect previously exposed individuals (Aitken et al., 2008), to trans-
mit directly by cell–cell routes in vitro (Brimacombe et al., 2011;
Timpe et al., 2007) and to evolve neutralization escape variants
(Shimizu et al., 1994) makes the development of a HCV vaccine a
major challenge. However the existence of natural immunity to
infection in some humans (Mehta et al., 2002) and chimpanzees
(Bassett et al., 2001; Farci et al., 1992; Lanford et al., 2004; Weiner
et al., 2001) is encouraging and suggests that the immune system
can eliminate infection. Immunization of chimpanzees with re-
combinant preparations of HCV glycoprotein protected animals
from challenge with autologous virus (Choo et al., 1994). Of note,
in animals with reduced antibody responses (Choo et al., 1994)
and those challenged with heterologous virus (Nattermann et al.,
2005), sterilizing immunity was not achieved (Puig et al., 2004;
Youn et al., 2005) however, the animals failed to progress to a
chronic state of infection. Reports on the immunogenicity of re-
combinant HCV glycoproteins in mice and non-human primates
are variable (Elmowalid et al., 2007; Jeong et al., 2004; Lechmann
et al., 2001; Murata et al., 2003; Qiao et al., 2003; Stamataki
et al., 2007), with higher titer antibody responses generally
observed in mice.
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vated HCVcc (Akazawa et al., 2013) or virus-like particle pseudo-
typed with HCV glycoproteins (Garrone et al., 2011) to protect
mice or macaques, respectively against HCV challenge. Impor-
tantly, vaccination of healthy volunteers with HCV-1 E1E2 glyco-
proteins elicited serum antibody responses that were able to
neutralize heterologous HCVpp and HCVcc in vitro and were
detectable one year post vaccination (Law et al., 2013; Stamataki
et al., 2011), highlighting a number of promising vaccine candidate
leads. Ideally, any future vaccine should induce both T cell and B
cell immunity and studies to optimize a combined regimen includ-
ing the recently reported adenovirus-based HCV T cell vaccine
(Barnes et al., 2012) ⁄with recombinant E1E2 protein boost will
be valuable. Recent studies showing the efﬁcacy of passive admin-
istration of polyclonal anti-HCV Ig (Meuleman et al., 2011) and
anti-E2 neutralizing monoclonal antibodies (Law et al., 2008) in
preventing HCV infection of mouse models, highlight the value of
neutralizing monoclonal antibodies for therapeutic or prophylactic
purposes.8. HCV glycoprotein structure
Receptor and antibody mapping studies have increased our
understanding of the topology of key antigenic and functional
determinants of the HCV glycoproteins. Competition assays with
a panel of neutralizing and non-neutralizing antibodies led to the
development of a three-domain structure for E2 glycoprotein with
domains A, B and C containing non-neutralizing and broad andFig. 3. Antigenic organization of the HCV glycoprotein E2 core structure. The surface o
monoclonal antibody epitopes (labelled on the periphery of the regions) using compleme
Neutralizing antibodies are labelled in red, while non-neutralizing antibodies are labelle
domains highlight the CD81 binding region, possessing conserved neutralization epitopes
circle), and a less organized region that includes epitopes of non-neutralizing mAbs (yello
that is partially formed by a helical region between aa 428–442 (burgundy oval). Disulﬁde
within primary amino acid chain indicated by dashed lines.restricted neutralizing epitopes, respectively (Keck et al., 2005,
2004). Additional studies highlighted the discontinuous nature
of E2 CD81 binding site (Clayton et al., 2002; Flint et al., 1999a;
Owsianka et al., 2001), that informed the development of alanine
replacement glycoprotein panels that facilitated ﬁne detail
mapping of this key receptor binding site (Drummer et al., 2006;
Owsianka et al., 2006; Rothwangl et al., 2008).
Whilst most potent and broad neutralizing antibodies recognize
conformational epitopes a limited number have been shown to
bind linear epitopes. One of the ﬁrst conserved linear neutralizing
determinants to be described was the region of E2 encompassing
aa 412–423, that is targeted by murine AP33 (Owsianka et al.,
2005) and 3/11 (Flint et al., 1999b) and human monoclonal anti-
bodies HCV1 (Broering et al., 2009) and HC33 (Keck et al., 2013)).
Our early studies demonstrated that antibodies targeting this re-
gion were capable of potent and broad neutralization (Owsianka
et al., 2005; Tarr et al., 2006), so understandably this epitope has
been the subject of interest in terms of vaccine design. Epitope
mapping studies highlighted that each of these antibodies target
overlapping, but distinct epitopes (Broering et al., 2009; Keck
et al., 2013; Tarr et al., 2006) and this may explain their differing
neutralizing potency and breadth.
The recently described E2 crystal structure (Kong et al., 2013)
has provided an important framework to delineate the molecular
interactions with CD81 and broadly neutralizing antibodies, con-
ﬁrming many of the salient points concluded from earlier receptor
and antibody epitope mapping experiments. The E2 protein is
mainly globular and the surface features include a neutralizing
face, containing cross-reactive and strain-restricted (variable)f E2 is categorized into three partially-overlapping antigenic regions, that include
ntary techniques of binding competition assays and, alanine scanning mutagenesis.
d in green. When mapped onto the crystal structure of E2 (Kong et al., 2013), these
(blue circle), a b-sheet possessing less well conserved neutralization epitopes (pink
w circle). An additional region containing neutralization epitopes was also revealed,
bonds stabilizing the structure are highlighted in yellow, and unresolved structures
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cluded on the intact virus particle (Fig. 3). Importantly, E2 residues
previously reported play a role in CD81 binding (Owsianka et al.,
2006; Tarr et al., 2006) and binding neutralizing antibodies
(Johansson et al., 2007; Law et al., 2008; Owsianka et al., 2005,
2008; Perotti et al., 2008) were juxtaposed on the E2 tertiary struc-
ture, highlighting the importance of this region in antibody-based
vaccine design (Fig. 4).
Recently, two groups reported the crystal structure of AP33 and
HCV1 bound to their cognate peptide including aa 412–423 pep-
tide. The key contact residues conﬁrmed previous epitope mapping
data and showed this region to adopt a beta-hairpin structure and
peptide–antibody binding comprising largely hydrophobic interac-
tions (Kong et al., 2012a,b; Potter et al., 2012), providing insights
on epitope presentation that may be needed to elicit protective
antibodies. Intriguingly, this region was unresolved in the recently
reported E2 core structure (Kong et al., 2013), suggesting that it
may be constrained by regions not present in the crystallized pro-
tein preparation – possibly HVR1, that is known to modulate the
CD81 binding site and epitope exposure (Bankwitz et al., 2010).
Alternatively, this region could be ﬂexible and adopt several con-
formations at the virion surface, only some of which are recognized
by speciﬁc neutralizing antibodies.
Structural studies of neutralizing antibodies in complex with
their peptide targets is starting to reveal how some antibodies
can maintain potency in the face of viral evolution. For example,
analysis of human mAbs HC84-1 and HC84-27 in complex with
E2 peptide aa 434–446 shows that some of the key E2 contact res-
idues are variable. Close inspection of variant amino acids reveals
that the overall property of the amino acids is conserved and this
may explain the cross-reactive phenotype of these antibodies (Krey
et al., 2013). However, this region contains overlapping yet distinct
epitopes (Tarr et al., 2012) and amino acid variability in this region
can abrogate binding of other neutralizing antibodies (Deng et al.,Fig. 4. Speciﬁc residues deﬁning receptor binding sites and antibody binding residues on
the reported structure (Kong et al., 2013) (PDB reference 4MWF). (A) Residues involved
neutralizing mAb AR1B (N540, W549); (C) neutralizing mAb AR3A (S424, G523, P525, G5
neutralizing mAb 1:7 (G523, W529, G530 D535); and (F) the restricted neutralizing mAb
discrete neutralizing epitope clusters on the core E2 structure, and the lack of neutraliz2013). Given these observations, designing immunogens that elicit
antibodies capable of accommodating this sequence variability will
be challenging. Peptide-based vaccines would be easy to produce
but unconstrained peptides can adopt a myriad of conformations,
only some of which would may protective antibody responses.
Increasing our knowledge of the molecular and structural determi-
nants involved in key neutralizing antibody-epitope interactions
could greatly facilitate rational design of future vaccine candidates.9. Future challenges and prospects
Despite the advent of increasingly effective treatments, the
need for a preventive HCV vaccine has not waned. Development
of antibody-based therapeutics or vaccines requires a greater
understanding of the protective antibody response. A major short-
fall is that much of our current understanding has been derived
from studying human antibodies obtained during chronic infection
or through experimental immunization of small animals. One may
argue that the most protective antibodies are likely to be present
during acute resolved infection (Logvinoff et al., 2004; Osburn
et al., 2014; Pestka et al., 2007), yet very little is known about
the nature and speciﬁcity of these antibody responses. Application
of improved methods to isolate human monoclonal antibodies,
including clonal sorting (Scheid et al., 2009; Smith et al., 2009; Tiller
et al., 2008; Wu et al., 2010) and short-term culture (Corti et al.,
2011; Walker et al., 2009), together with techniques to fractionate
and analyse the polyclonal response (Li et al., 2007, 2009), will help
resolve this shortfall. Functional screening of short-term B-/plasma
cell cultures has the potential to identify neutralizing antibodies
targeting novel epitopes; an approach that has yielded several
potent anti-HIV and inﬂuenza-speciﬁc human monoclonal
antibodies (Corti et al., 2011; Walker et al., 2009). This would be
possible through identiﬁcation of protective antibodythe core HCV E2 glycoprotein structure. Important residues are highlighted in red on
in the CD81 binding site (G523, W529, G530, D535); (B) binding residues for non-
30, D535, N540); (D) neutralizing mAb HC84.22 (N428, W437, L441, F442, Y443); (E)
2/69a (G440, Y443, K446). These images highlight the overlapping nature of the two
ing epitopes in the regions of the protein highlighted in orange, yellow and green.
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screening methods that speciﬁcally enrich/isolate antibodies tar-
geting conserved regions of the viral glycoprotein involved in virus
entry.
Immunization strategies that rely solely upon the administra-
tion of unmodiﬁed HCV subunits (e.g. E1E2 or soluble E2) are un-
likely to be successful, as the variable regions are
immunodominant (Puig et al., 2004). This scenario is similar to an-
other devastating chronic viral infection, HIV-1, where current vac-
cine efforts focus on engineered immunogens (Ahmed et al., 2012;
Pantophlet and Burton, 2003; Walker and Burton, 2010). This im-
mune-focused approach has been facilitated by the isolation and
characterisation of neutralizing human antibodies (e.g. 2F5, 2G12
and IgG-b12) that target distinct steps in the viral entry pathway
(Moore et al., 1994; Pantophlet et al., 2003a,b; Saphire et al.,
2001, 2002; Zwick et al., 2003). The recent elucidation of the crys-
tal structure of HCV E2 (Kong et al., 2013) will undoubtedly pave
the way for similar approaches in HCV vaccine development.10. Conclusions
Studies of the HCV neutralizing response have contributed
greatly to our understanding of the natural progression of hepatitis
C virus infection. There is increasing evidence that the speciﬁcity
and potency of the early antibody response can inﬂuence acute
infection outcome and neutralizing antibodies seem to play a part
in controlling HCV during chronic infection. Emerging in vitro and
in vivo systems is enabling us to gain a better understanding of the
antibody determinants that lead to protection. Undoubtedly, one of
the major challenges for the future will be to harness this knowl-
edge for the development of effective antibody-based vaccines
and treatments.
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